Wednesday, 20 Nov 2019

You are here

Ustekinumab Efficacy in Ulcerative Colitis

The NEJM reports the results of a one year trial wherein ustekinumab (UST) was shown to be effective at inducing and maintaining remission in patients with moderate-to-severe ulcerative colitis. Ustekinumab, currently approved for use in psoriasis, psoriatic arthritis and Crohn's disease, is a monoclonal antibody against the p40 subunit of interleukin-12 and interleukin-23.

The study included 961 patients with moderate-to-severe ulcerative colitis who received intravenous placebo (PBO) or UST as 8-week induction therapy and 44-week maintenance therapy in patients. The primary end point was clinical remission (defined as a total score of ≤2 on the Mayo scale).

At the end of 8 weeks, clinical remission was significantly higher with ustekinumab 130 mg (15.6%) or 6 mg/kg (15.5%) than that placebo (5.3%) (P<0.001). 

Responders to induction therapy also had higher clinical remission rates at week 44 with 90 mg subcutaneous UST (q 12 wks) (38.4%) or every 8 weeks (43.8%) than among those assigned to placebo (24.0%) (P=0.002 and P<0.001, respectively).

Serious adverse events were similar between UST and PBO. At one year there were two deaths and cancers in the 825 UST treated patients compared to no deaths and one cancer for the 319 patients on PBO.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

ACR 2019 – Best of the Plenary Sessions

The ACR Plenary Sessions featured some of the best research presented on Sunday, Monday, and Tuesday in Atlanta. Here are my seven notable highlights from the Plenaries.

New EMA Warnings for Tofacitinib in Patients at Risk for Clots

The European Medicines Agency safety committee (PRAC) has concluded that Xeljanz (tofacitinib - TOFA) could increase the risk of blood clots in the lungs and in deep veins in patients who are already at high risk for venous thromboembolic events. The PRAC is recommending that TOFA should be used with caution in patients at high risk of blood clots (VTE), regardless of dose used.

FDA Approves Ustekinumab for Ulcerative Colitis

Ustekinumab (Stelara) is now FDA-approved to treat moderately to severely active ulcerative colitis, said drugmaker Janssen on Monday, in addition to its indications for psoriasis, psoriatic arthritis, and Crohn's disease.

Interleukin Targeted Biologics Increase Risks of Infection

A systematic review of the literature shows that, compared to placebo, the use of non-TNF, interleukin inhibitor biologics may be associated with significantly higher rates of serious infections, opportunistic infections, and cancer.

Biologics Lead the Way in Drug Price Increases

Reuters has reported the results of a recent Institute for Clinical and Economic Review (ICER) analysis showing that biologics, especially Humira and Rituxan, are leading the way in the cost of drugs in the USA. All told, Humira and Rituxan topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. drug spending. ICER said their analysis points to price hikes that were more than twice the rate of medical inflation and were not warranted by any new clinical evidence.